Caro Gen Corporation
Biotechnology, 400 Farmington Ave 2802, Farmington, Connecticut, 06032, United States, 1-10 Employees
Phone Number: 20********
Who is CAROGEN CORPORATION
CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently exe...
Read More
-
Headquarters: 400 Farmington Ave 2802, Farmington, Connecticut, 06032, United States
-
Date Founded: 2012
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 999990 |
Show More
Does something look wrong? Fix it. | View contact records from CAROGEN CORPORATION
CaroGen Corporation Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CaroGen Corporation
Answer: CaroGen Corporation's headquarters are located at 400 Farmington Ave 2802, Farmington, Connecticut, 06032, United States
Answer: CaroGen Corporation's phone number is 20********
Answer: CaroGen Corporation's official website is https://carogencorp.com
Answer: CaroGen Corporation's revenue is $1 Million to $5 Million
Answer: CaroGen Corporation's SIC: 2834
Answer: CaroGen Corporation's NAICS: 999990
Answer: CaroGen Corporation has 1-10 employees
Answer: CaroGen Corporation is in Biotechnology
Answer: CaroGen Corporation contact info: Phone number: 20******** Website: https://carogencorp.com
Answer: CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the bodys immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month